Literature DB >> 12403002

Peptidergic mechanisms of hyperthermia-evoked convulsions in rats in early postnatal ontogenesis.

N E Chepurnova1, A A Ponomarenko, S A Chepurnov.   

Abstract

This report addresses the verification of the hypothesis that arginine-vasopressin affects the formation of hyperthermia-evoked convulsions in early ontogenesis in rats on days 3, 5, 7, and 9 of postnatal life. The modification of experimental febrile convulsions by PACAP (pituitary adenylate cyclase-activating peptide) was investigated; PACAP is a physiological regulator of the neurosecretion of arginine-vasopressin. Arginine-vasopressin (10 microg/rat) and PACAP (0.01 microg/rat) decreased the latency of generalized tonic-clonic convulsions and the time of truncal generalization of convulsive activity on days 3 and 5 of rat development. Animals given arginine-vasopressin (0.1-10 microg/rat) sowed significant increases in the duration of generalized convulsions to the level of status epilepticus on day 9 of life. Conversely, administration of higher doses of PACAP (0.1 microg/rat) increased the threshold of tonic-clonic convulsions on days 3 and 5 and decreased it on days 7 and 9 of postnatal development. The indirect involvement of PACAP in the mechanisms of experimental febrile convulsions is suggested to act via changes in arginine-vasopressin neurosecretion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403002     DOI: 10.1023/a:1019807622531

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  28 in total

1.  Galanin immunoreactive neurons in the human hypothalamus: colocalization with vasopressin-containing neurons.

Authors:  W P Gai; L B Geffen; W W Blessing
Journal:  J Comp Neurol       Date:  1990-08-15       Impact factor: 3.215

2.  Effect of spinal cord injury on the permeability of the blood-brain and blood-spinal cord barriers to the neurotropin PACAP.

Authors:  W A Banks; A J Kastin; A Arimura
Journal:  Exp Neurol       Date:  1998-05       Impact factor: 5.330

3.  Thermoregulatory activity of sodium nitroprusside and arginine vasopressin.

Authors:  I T Gagało; E E Hać; M T Matuszek; P Rekowski; G Kupryszewski; K Z Korolkiewicz
Journal:  Gen Pharmacol       Date:  1995-03

4.  Galanin controls excitability of the brain.

Authors:  S A Chepurnov; N E Chepurnova; R K Berdiev
Journal:  Ann N Y Acad Sci       Date:  1998-12-11       Impact factor: 5.691

5.  Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments.

Authors:  D de Wied
Journal:  Life Sci       Date:  1976-09-01       Impact factor: 5.037

Review 6.  The role of vasopressin as an antipyretic in the ventral septal area and its possible involvement in convulsive disorders.

Authors:  Q J Pittman; A Naylor; P Poulin; J Disturnal; W L Veale; S M Martin; T J Malkinson; B Mathieson
Journal:  Brain Res Bull       Date:  1988-06       Impact factor: 4.077

7.  Kindling of the hippocampus and septum in vasopressin-deficient rats (Brattleboro strain).

Authors:  B J Gillis; D P Cain
Journal:  Brain Res       Date:  1986-01-22       Impact factor: 3.252

8.  On the blood-brain barrier to peptides: accumulation of labelled vasopressin, DesGlyNH2-vasopressin and oxytocin by brain regions.

Authors:  A Ermisch; T Barth; H J Rühle; J Skopková; P Hrbas; R Landgraf
Journal:  Endocrinol Exp       Date:  1985-03

9.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons. Evidence for a cAMP-independent mechanism.

Authors:  N Stella; P J Magistretti
Journal:  J Biol Chem       Date:  1996-09-27       Impact factor: 5.157

10.  Pituitary adenylate cyclase-activating polypeptide stimulates arginine vasopressin release in conscious rats.

Authors:  T Murase; K Kondo; K Otake; Y Oiso
Journal:  Neuroendocrinology       Date:  1993-06       Impact factor: 4.914

View more
  1 in total

Review 1.  Neuropeptides as targets for the development of anticonvulsant drugs.

Authors:  Elke Clynen; Ann Swijsen; Marjolein Raijmakers; Govert Hoogland; Jean-Michel Rigo
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.